The proteosomal degradation of fusion proteins cannot be predicted from the proteosome susceptibility of their individual components

Protein Science

Volumn 17, Issue 6, 2008, Pages 1077-1085

  Ilyinskii, Petr O ^a   Meriin, Anatoli B ^b   Gabai, Vladimir L ^b   Usachev, Evgeny V ^c   Prilipov, Alexei G ^c   Thoidis, Galini ^a   Shneider, Alexander M ^a  

^a Cure Lab Inc   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c D I IVANOVSKY INSTITUTE OF VIROLOGY   (Russian Federation)

Author keywords

Chimeric proteins; Proteosome degradation and resistance

Indexed keywords

CHIMERIC PROTEIN; HYBRID PROTEIN; INFLUENZA VACCINE; MUTANT PROTEIN; NONSTRUCTURAL PROTEIN 1; NUCLEOPROTEIN; PROTEIN M1; PROTEIN M2; PROTEOME; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CHIMERA; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; INFLUENZA VIRUS; MULTIGENE FAMILY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN ENGINEERING; PROTEIN STABILITY; VACCINE PRODUCTION; WILD TYPE;

HYDROLYSIS; ORTHOMYXOVIRIDAE; PROTEASOME ENDOPEPTIDASE COMPLEX; RECOMBINANT FUSION PROTEINS; VIRAL PROTEINS;

EID: 44349118015     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1110/ps.083443908     Document Type: Article

References (40)

1. Akarsu, H., Burmeister, W.P., Petosa, C., Petit, I., Muller, C.W., Ruigrok, R.W., and Baudin, F. 2003. Crystal structure of the M1 protein-binding domain of the influenza A virus nuclear export protein (NEP/NS2). EMBO J. 22: 4646-4655.
2. Altstein, A.D., Gitelman, A.K., Smirnov, Y.A., Piskareva, L.M., Zakharova, L.G., Pashvykina, G.V., Shmarov, M.M., Zhirnov, O.P., Varich, N.P., Ilyinskii, P.O., et al. 2006. Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses. Arch. Virol. 151: 921-931.
3. Antón, L.C., Schubert, U., Bacík, I., Princiotta, M.F., Wearsch, P.A., Gibbs, J., Day, P.M., Realini, C., Rechsteiner, M.C., Bennink, J.R., et al. 1999. Intracellular localization of proteasomal degradation of a viral antigen. J. Cell Biol. 146: 113-124.
4. Blazevic, V., Männik, A., Malm, M., Sikut, R., Valtavaara, M., Toots, U., Ustav, M., and Krohn, K. 2006. Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-MultiHIV DNA vaccine. AIDS Res. Hum. Retroviruses 22: 667-677.
5. Chen, Z., Sahashi, Y., Matsuo, K., Asanuma, H., Takahashi, H., Iwasaki, T., Suzuki, Y., Aizawa, C., Kurata, T., and Tamura, S. 1998. Comparison of the ability of viral protein-expressing plasmid DNAs to protect against influenza. Vaccine 16: 1544-1549.
6. Chen, Z., Yoshikawa, T., Kadowaki, S., Hagiwara, Y., Matsuo, K., Asanuma, H., Aizawa, C., Kurata, T., and Tamura, S. 1999. Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein. J. Gen. Virol. 80: 2559-2564.
7. De Filette, M., Min Jou, W., Birkett, A., Lyons, K., Schultz, B., Tonkyro, A., Resch, S., and Fiers, W. 2005. Universal influenza A vaccine: Optimization of M2-based constructs. Virology 337: 149-161.
8. De Filette, M., Fiers, W., Martens, W., Birkett, A., Ramne, A., Lowenadler, B., Lycke, N., Min Jou, W., and Saelens, X. 2006. Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 24: 6597-6601.
9. Elster, C., Larsen, K., Gagnon, J., Ruigrok, R.W., and Baudin, F. 1997. Influenza virus M1 protein binds to RNA through its nuclear localization signal. J. Gen. Virol. 78: 1589-1596.
10. + T cells can promote survival and recovery after challenge. Int. Immunol. 12: 91-101.
11. Epstein, S., Tumpey, T.M., Misplon, J.A., Lo, C.Y., Cooper, L.A., Subbarao, K., Renshaw, M., Sambhara, S., and Katz, J.M. 2002. DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg. Infect. Dis. 8: 796-801.
12. Epstein, S., Kong, W.P., Misplon, J.A., Lo, C.Y., Tumpey, T.M., Xu, L., and Nabel, G.J. 2005. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23: 5404-5410.
13. Fiers, W., De Filette, M., Birkett, A., Neirynck, S., and Min Jou, W. 2004. A "universal" human influenza A vaccine. Virus Res. 103: 173-176.
14. Garcia-Robles, I., Akarsu, H., Muller, C.W., Ruigrok, R.W., and Baudin, F. 2005. Interaction of influenza virus proteins with nucleosomes. Virology 332: 329-336.
15. Goldberg, A.L. 2007. Functions of the proteasome: From protein degradation and immune surveillance to cancer therapy. Biochem. Soc. Trans. 35: 12-17.
16. Ilyinskii, P.O., Gabai, V.L., Sunyaev, S.R., Thoidis, G., and Shneider, A.M. 2007. Toxicity of influenza A virus matrix protein 2 for mammalian cells is associated with its intrinsic proton-channeling activity. Cell Cycle 6: 2043-2047.
17. Ilyinskii, P.O., Gambaryan, A.S., Meriin, A.B., Gabai, V., Kartashov, A., Thoidis, G., and Shneider, A.M. 2008a. Inhibition of influenza M2-induced cell death alleviates its negative contribution to vaccination efficiency. PLoS ONE 3: e1417. doi: 10.1371/journal.pone.00001417.
18. Ilyinskii, P.O., Meriin, A.B., Gabai, V.L., Zhirnov, O.P., Thoidis, G., and Shneider, A.M. 2008b. Prime-boost vaccination with a combination of proteosome-degradable and wild-type forms of two influenza proteins leads to augmented CTL response. Vaccine (in press). doi: 10.1016/j.vaccine.2008. 02.050.
19. Jensen, P.E. 2007. Recent advances in antigen processing and presentation. Nat. Immunol. 8: 1041-1048.
20. Jimenez, G.S., Planchon, R., Wei, Q., Rusalov, D., Geall, A., Enas, J., Lalor, P., Leamy, V., Vahle, R., Luke, C.J., et al. 2007. Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum. Vaccin. 3: 157-164.
21. Kmieciak, D., Bolesta, E., Naito, T., Gzyl, J., Kaneko, Y., and Kozbor, D. 2001. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens. J. Hum. Virol. 4: 306-316.
22. Kummerfeld, S.K. and Teichmann, S.A. 2005. Relative rates of gene fusion and fission in multi-domain proteins. Trends Genet. 21: 25-30.
23. Lee, D.H. and Goldberg, A.L. 1998. Proteasome inhibitors: Valuable new tools for cell biologists. Trends Cell Biol. 8: 397-403.
24. Niwa, H., Yamamura, K., and Miyazaki, J. 1991. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108: 193-199.
25. Noton, S.L., Medcalf, E., Fisher, D., Mullin, A.E., Elton, D., and Digard, P. 2007. Identification of the domains of the influenza A virus M1 matrix protein required for NP binding, oligomerization and incorporation into virions. J. Gen. Virol. 88: 2280-2290.
26. Prlic, M., Williams, M.A., and Bevan, M.J. 2007. Requirements for CD8 T-cell priming, memory generation and maintenance. Curr. Opin. Immunol. 19: 315-319.
27. Restifo, N.P., Bacik, I., Irvine, K.R., Yewdell, J.W., McCabe, B.J., Anderson, R.W., Eisenlohr, L.C., Rosenberg, S.A., and Bennink, J.R. 1995. Antigen processing in vivo and the elicitation of primary CTL responses. J. Immunol. 154: 4412-4422.
28. Scriba, T.J., zur Megede, J., Glashoff, R.H., Treurnicht, F.K., Barnett, S.W., and van Rensburg, E.J. 2005. Functionally inactive and immunogenic Tat, Rev and Nef DNA vaccines derived from sub-Saharan subtype C human immunodeficiency virus type 1 consensus sequences. Vaccine 23: 1158-1169.
29. Shinoda, K., Xin, K.Q., Jounai, N., Kojima, Y., Tamura, Y., Okada, E., Kawamoto, S., Okuda, K., Klinman, D., and Okuda, K. 2004. Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice. Vaccine 22: 3676-3690.
30. Slepushkin, V.A., Katz, J.M., Black, R.A., Gamble, W.C., Rota, P.A., and Cox, N.J. 1995. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 13: 1399-1402.
31. Starodubova, E., Boberg, A., Kashuba, E.V., Wahren, B., Karpov, V., and Isaguliants, M. 2006. HIV-1 reverse transcriptase targeted for proteasomal degradation as a prototype vaccine against drug-resistant HIV-1. Vaccine 24: 4541-4547.
32. Stoloff, G.A. and Caparros-Wanderley, W. 2007. Synthetic multi-epitope peptides identified in silico induce protective immunity against multiple influenza serotypes. Eur. J. Immunol. 37: 2441-2449.
33. Tompkins, S., Zhao, Z.S., Lo, C.Y., Misplon, J.A., Liu, T., Ye, Z., Hogan, R.J., Wu, Z., Benton, K.A., Tumpey, T.M., et al. 2007. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg. Infect. Dis. 13: 426-435.
34. Townsend, A., Bastin, J., Gould, K., Brownlee, G., Andrew, M., Coupar, B., Boyle, D., Chan, S., and Smith, G. 1988. Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J. Exp. Med. 168: 1211-1224.
35. Wong, S.B.J., Buck, C.B., Shen, X., and Siliciano, R.F. 2004. An evaluation of enforced rapid proteasomal degradation as a means of enhancing vaccine-induced CTL responses. J. Immunol. 173: 3073-3083.
36. Wu, Y. and Kipps, T.J. 1997. Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T lymphocytes. J. Immunol. 159: 6037-6043.
37. Ye, Q., Krug, R.M., and Tao, Y.J. 2006. The mechanism by which influenza A virus nucleoprotein forms oligomers and binds RNA. Nature 444: 1078-1082.
38. + T cells in vivo: The key to rational vaccine design. Annu. Rev. Immunol. 23: 651-682.
39. Zhang, M., Ishii, K., Hisaeda, H., Murata, S., Chiba, T., Tanaka, K., Li, Y., Obata, C., Furue, M., and Himeno, K. 2004. Ubiquitin-fusion degradation pathway plays an indispensable role in naked DNA vaccination with a chimeric gene encoding a syngeneic cytotoxic T lymphocyte epitope of melanocyte and green fluorescent protein. Immunology 112: 567-574.
40. Zhirnov, O., Isaeva, E.I., Konakova, T.E., Thoidis, G., Piskareva, L.M., Akopova, I.I., Kartashov, A., Altstein, A.D., Ilyinskii, P.O., and Shneider, A.M. 2007. Protection against mouse and avian influenza A strains via vaccination with a combination of conserved proteins NP, M1 and NS1. Influenza Other Respir. Viruses 1: 71-79.